SEC filings and other documents

Q1 sales and EPS beat expectations; FY27 outlook raised amid ongoing cost and supply risks.

All proposals passed, with a renewed focus on operational excellence and consumer-driven growth.

Q4 outperformed expectations; FY 2027 targets growth, innovation, and further debt reduction.

Prioritizing high-growth brands, revenue focus, and global expansion to drive long-term value.

Net sales declined 3.4% year-over-year, but key brands outperformed and innovation investment continues.

Sales and margins declined amid tariffs, but innovation and cost actions aim to restore growth.

Tariffs and consumer trade-down drove Q1 declines, but recovery is expected in the year's second half.

All proposals, including director elections and compensation, passed by majority vote.

Q4 met expectations, but FY26 faces $200M+ tariff risk with 70%-80% mitigation planned.

Brand revitalization, strategic acquisition, and operational efficiency drive growth and margin gains.

Home and outdoor growth offset weak wellness sales; Olive & June acquisition boosts outlook.